US 11,896,558 B2
Use of an RXR agonist and taxanes in treating Her2+ cancers
Martin E. Sanders, Spring, TX (US); Powel H. Brown, Houston, TX (US); Cassandra Moyer, Houston, TX (US); and Abhijit Mazumdar, Houston, TX (US)
Assigned to Io Therapeutics, Inc., Spring, TX (US); and Board of Regents, The University of Texas System, Austin, TX (US)
Filed by Io Therapeutics, Inc., Spring, TX (US); and Board of Regents, The University of Texas System, Austin, TX (US)
Filed on Dec. 7, 2022, as Appl. No. 18/076,992.
Claims priority of provisional application 63/286,986, filed on Dec. 7, 2021.
Prior Publication US 2023/0172872 A1, Jun. 8, 2023
Int. Cl. A61K 31/015 (2006.01); A61K 31/192 (2006.01); A61P 35/00 (2006.01); A61K 45/06 (2006.01); A61K 31/56 (2006.01)
CPC A61K 31/015 (2013.01) [A61K 31/192 (2013.01); A61K 31/56 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01)] 11 Claims
 
1. A method of treating a Her2+ cancer in a patient in need thereof comprising administering a taxane and a RXR agonist of Formula I,

OG Complex Work Unit Chemistry
wherein R is H, or lower alkyl of 1 to 6 carbons, or a pharmaceutically-acceptable salt thereof, to the patient.